JP2016504315A - 三価デングウイルス製剤に関する組成物、投与方法および使用 - Google Patents

三価デングウイルス製剤に関する組成物、投与方法および使用 Download PDF

Info

Publication number
JP2016504315A
JP2016504315A JP2015547441A JP2015547441A JP2016504315A JP 2016504315 A JP2016504315 A JP 2016504315A JP 2015547441 A JP2015547441 A JP 2015547441A JP 2015547441 A JP2015547441 A JP 2015547441A JP 2016504315 A JP2016504315 A JP 2016504315A
Authority
JP
Japan
Prior art keywords
dengue
virus
vaccine
dengue virus
den
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504315A5 (cg-RX-API-DMAC7.html
Inventor
ティ． スティンチコム、ダン
ティ． スティンチコム、ダン
エヌ． ブレウー、ジョセフ
エヌ． ブレウー、ジョセフ
オソリオ、ジョージ
ディ． パーチドス、カラランボス
ディ． パーチドス、カラランボス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2016504315A publication Critical patent/JP2016504315A/ja
Publication of JP2016504315A5 publication Critical patent/JP2016504315A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015547441A 2012-12-14 2013-12-07 三価デングウイルス製剤に関する組成物、投与方法および使用 Pending JP2016504315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737679P 2012-12-14 2012-12-14
US61/737,679 2012-12-14
PCT/US2013/073757 WO2014093182A1 (en) 2012-12-14 2013-12-07 Compositions, methods of administration and uses for trivalent dengue virus formulations

Publications (2)

Publication Number Publication Date
JP2016504315A true JP2016504315A (ja) 2016-02-12
JP2016504315A5 JP2016504315A5 (cg-RX-API-DMAC7.html) 2017-01-26

Family

ID=50934851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547441A Pending JP2016504315A (ja) 2012-12-14 2013-12-07 三価デングウイルス製剤に関する組成物、投与方法および使用

Country Status (5)

Country Link
US (2) US9878031B2 (cg-RX-API-DMAC7.html)
EP (1) EP2931310A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016504315A (cg-RX-API-DMAC7.html)
CA (1) CA2933472A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014093182A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3539565T3 (fi) * 2013-03-15 2023-04-19 Takeda Vaccines Inc Koostumuksia ja menetelmiä dengue-viruksen kimeerisille rakenteille rokotteissa
WO2016130786A2 (en) * 2015-02-15 2016-08-18 Integral Molecular, Inc. Flaviviridae proteins and virions and methods of use thereof
CN120392993A (zh) * 2016-04-13 2025-08-01 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
AU2020331884B2 (en) * 2019-08-16 2025-01-23 Takeda Vaccines, Inc. Methods for preventing dengue and Hepatitis A
CN120225693A (zh) * 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505801A (ja) * 2006-10-04 2010-02-25 サノフィ・パスツール ４種のデング血清型に対する免疫付与の方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
US20040120964A1 (en) 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
EP1891210B1 (en) 2005-06-17 2010-07-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
BRPI0613328A2 (pt) * 2005-06-17 2011-01-04 Sanofi Pasteur cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
US8337860B2 (en) 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
WO2010085358A2 (en) 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
CA2763944A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
WO2013188315A1 (en) 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US20120294889A1 (en) 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505801A (ja) * 2006-10-04 2010-02-25 サノフィ・パスツール ４種のデング血清型に対する免疫付与の方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＴＲＯＰＩＣＡＬ ＭＥＤＩＣＩＮＥ ＡＮＤ ＨＹＧＩＥＮＥ, vol. 22, no. 3, JPN5009017937, 1973, pages 375 - 381, ISSN: 0004004105 *
ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＴＲＯＰＩＣＡＬ ＭＥＤＩＣＩＮＥ ＡＮＤ ＨＹＧＩＥＮＥ, vol. 22, no. 3, JPN6012047727, 1973, pages 365 - 374, ISSN: 0004004108 *
ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＴＲＯＰＩＣＡＬ ＭＥＤＩＣＩＮＥ ＡＮＤ ＨＹＧＩＥＮＥ, vol. 80, no. 2, JPN6017033314, 2009, pages 302 - 311, ISSN: 0004004109 *
N. BHAMARAPRAVATI. ET AL.: "The clinical trial of trivalent dengue vaccine.", ＳＯＵＴＨＥＡＳＴ ＡＳＩＡＮ ＪＯＵＲＮＡＬ ＯＦ ＴＲＯＰＩＣＡＬ ＭＥＤＩＣＩＮＥ ＡＮＤ Ｐ, vol. 21, no. 4, JPN6017033309, 1990, pages 709, ISSN: 0004004106 *
ＶＡＣＣＩＮＥ, vol. 18, no. 2, JPN6017033311, 2000, pages 44 - 47, ISSN: 0004004107 *
ＶＡＣＣＩＮＥ, vol. 29, no. 42, JPN6017033317, 2011, pages 7251 - 7260, ISSN: 0004004111 *
臨床と微生物, vol. 29, no. 2, JPN6012047713, 2002, pages 25 - 29, ISSN: 0004004110 *

Also Published As

Publication number Publication date
EP2931310A1 (en) 2015-10-21
EP2931310A4 (en) 2016-05-25
US20180228887A1 (en) 2018-08-16
CA2933472A1 (en) 2014-06-19
WO2014093182A1 (en) 2014-06-19
US20150335727A1 (en) 2015-11-26
US9878031B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
Osorio et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever
JP6486827B2 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する核酸分子、組成物および使用
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
JP3681358B2 (ja) キメラおよび／または増殖制限されたフラビウイルス
US9713638B2 (en) Compositions and methods for rapid immunization against dengue virus
US8088391B2 (en) West nile virus vaccine
US9878031B2 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
CA2432370C (en) Attenuated flaviviral live vaccine comprising a capsid protein deletion
JP2018090618A (ja) デングウイルスに対する免疫原性組成物およびワクチンキット
JP2007525226A (ja) フラビウイルスワクチン
CN103031279B (zh) 重组黄病毒疫苗
CA2622827C (en) Pharmaceutical compound capable of inducing immune protective response against dengue virus having the capsid protein of the dengue virus
EP2339011B1 (en) West Nile virus and Dengue 4 virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
AU2019203166A1 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
HK1106723B (en) Vaccines against japanese encephalitis virus and west nile virus
HK1106723A1 (en) Vaccines against japanese encephalitis virus and west nile virus
HK1083192B (en) West nile virus vaccine
HK1120431A (en) Recombinant flavivirus vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190326